Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.61 |
| ▸ | CASP1 | P29466 | 12/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264008 | 1.00 | CTRB1 (0.61) | CTRB1CASP1SYKATMITGB3 | |
| SCHEMBL553906 | 1.00 | CTRB1 (0.61) | CTRB1CASP1SYKATMITGB3 | |
| SCHEMBL7136060 | 0.92 | CTRB1 (0.66) | CTRB1CASP1SYKATM | |
| SCHEMBL264153 | 0.92 | CTRB1 (0.56) | CTRB1CASP1SYKATM | |
| SCHEMBL4829896 | 0.91 | CTRB1 (0.68) | CTRB1SYKATM | |
| SCHEMBL25302472 | 0.88 | CTRB1 (0.58) | CTRB1CASP1SYKATMITGB3 | |
| SCHEMBL18956262 | 0.88 | CTRB1 (0.58) | CTRB1CASP1SYKATMITGB3 | |
| SCHEMBL14288626 | 0.88 | CTRB1 (0.58) | CTRB1CASP1SYKATM | |
| SCHEMBL6157326 | 0.88 | CTRB1 (0.74) | CTRB1CASP1ITGB3ITGA2B | |
| SCHEMBL6157333 | 0.88 | CTRB1 (0.74) | CTRB1CASP1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374020-A1 | SUBSTITUTED IMIDAZO[l,2-a]PYRAZINES AND PYRAZINO[l,2-a] PYRIMIDINES AS TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | Genesis Molecular Technologies, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230374020-A1 | SUBSTITUTED IMIDAZO[l,2-a]PYRAZINES AND PYRAZINO[l,2-a] PYRIMIDINES AS TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | Genesis Molecular Technologies, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-11639356-B2 | Substituted imidazo[1,2-a]pyrazines and pyrazino[1,2-a]pyrimidines as topical agents for dermatological applications | Genesis Molecular Technologies, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639356-B2 | Substituted imidazo[1,2-a]pyrazines and pyrazino[1,2-a]pyrimidines as topical agents for dermatological applications | Genesis Molecular Technologies, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| CN-115697967-A | Sulfonylbenzamide derivatives, conjugates thereof, preparation methods and applications of derivatives and conjugates | 江苏恒瑞医药股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220106320-A1 | TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | Genesis Molecular Technologies, Inc. | 2022-04-07 | — | — | US | disclosed |
| EP-2601177-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2017-10-18 | — | — | EP | disclosed |
| EP-2601177-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2017-10-18 | — | — | EP | disclosed |
| WO-2017123616-A1 | INHIBITING B-CELL LYMPHOMA 2 (BCL-2) AND RELATED PROTEINS | MERRIMACK PHARMACEUTICALS, INC. (US) | 2017-07-20 | — | — | WO | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| EP-1581475-A1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND DERIVATIVES THEREOF FROM D-AND L-ASPARTIC ACID | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2005-10-05 | — | — | EP | disclosed |
| US-6822115-B2 | VIA DIRECT HYDROLYSIS OF THE CHIRAL AMINOCARNITINE ESTER IN AN ACIDIC MILIEU TO YIELD A CHIRAL AMINOCARNITINE INNER SALT WITHOUT PURIFYING THE INTERMEDIATE PRODUCTS; PURITY OF >99%; RESOLUTION; ENZYME INHIBITOR OF CARNITINE PALMOYL TRANSFERASE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-11-23 | — | — | US | disclosed |
| WO-2004063143-A1 | SYNTHESIS FO (R) AND (S)-AMINOCARNITINE AND DERIVATIVES THEREOF FROM D-AND L-ASPARTIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-07-29 | — | — | WO | disclosed |
| US-20040102433-A1 | Novel beta-lactam compounds and process for producing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1340756-A1 | NOVEL BETA-LACTAM COMPOUNDS AND PROECSS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-09-03 | — | — | EP | disclosed |
| EP-1194398-B1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND THEIR DERIVATIVES STARTING FROM D- AND L-ASPARTIC ACID | SIGMA TAU IND FARMACEUTI (IT) | 2003-08-27 | — | — | EP | disclosed |
| US-20030153784-A1 | Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-08-14 | — | — | US | disclosed |
| US-6528684-B1 | Blocking amino group, cyclizing to anhydride, decarbonylation lactonation, hydrolysis, dehydroxylation quaternation using trimethyl ammonium halide, converting to internal carboxylic amine salt and deblocking | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-03-04 | — | — | US | disclosed |
| EP-1194398-A1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND THEIR DERIVATIVES STARTING FROM D- AND L-ASPARTIC ACID | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001002341-A1 | SYNTHESIS OF (R) AND (S)-AMINOCARNITINE AND THEIR DERIVATIVES STARTING FROM D- AND L-ASPARTIC ACID | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153784-A1 | Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid | BCAT1, BCAT2, DDC | CTRB1 2983/4885CASP1 2470/4885SYK 3419/4885 |
| US-20040102433-A1 | Novel beta-lactam compounds and process for producing the same | MRPL21, MCRS1, RPS4X | CTRB1 941/4885CASP1 135/4885SYK 2797/4885 |
| US-11639356-B2 | Substituted imidazo[1,2-a]pyrazines and pyrazino[1,2-a]pyrimidines as topical agents for dermatological applications | CREBBP, CREB1, PRKACA | CTRB1 2367/4885CASP1 2943/4885SYK 2848/4885 |
| US-20220106320-A1 | TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | CREBBP, EBP, CREB1 | CTRB1 1668/4885CASP1 2949/4885SYK 2735/4885 |
| US-20230374020-A1 | SUBSTITUTED IMIDAZO[l,2-a]PYRAZINES AND PYRAZINO[l,2-a] PYRIMIDINES AS TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS | CREBBP, CREB1, EP300 | CTRB1 2051/4885CASP1 3122/4885SYK 1613/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | CTRB1 2752/4885CASP1 89/4885SYK 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.